

Bruno C Medeiros

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/944110/bruno-c-medeiros-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

125
papers

5,766
citations

28
h-index

75
g-index

132
ext. papers

7,432
ext. citations

5.3
avg, IF

5.43
L-index

#	Paper	IF	Citations
125	Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia.. <i>Leukemia and Lymphoma</i> , 2022 , 1-7	1.9	
124	Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study.. <i>Leukemia and Lymphoma</i> , 2022 , 1-11	1.9	0
123	Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.. <i>Blood Advances</i> , 2021 ,	7.8	2
122	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021 , 35, 2539-2551	10.7	15
121	Plasma Microbial Cell-free DNA Next Generation Sequencing in the Diagnosis and Management of Febrile Neutropenia. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	15
120	Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. <i>Blood</i> , 2021 ,	2.2	6
119	Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e19005-e19005	2.2	
118	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , 2021 ,	10.7	4
117	Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020 , 26, 849-859	1.9	8
116	Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2700-2707	1.9	10
115	Functional characterization of two rare BCR-FGFR1 leukemias. <i>Journal of Physical Education and Sports Management</i> , 2020 , 6,	2.8	1
114	Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. <i>American Journal of Hematology</i> , 2020 , 95, 245-250	7.1	7
113	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020 , 4, 4945-4954	7.8	13
112	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020 , 135, 371-380	2.2	53
111	The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). <i>Leukemia Research</i> , 2019 , 78, 29-33	2.7	1
110	Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database. <i>Advances in Therapy</i> , 2019 , 36, 1922-1935	4.1	10
109	Addressing the room for improvement in management of acute promyelocytic leukemia. <i>European Journal of Haematology</i> , 2019 , 102, 479-485	3.8	4

108	Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey. <i>Current Medical Research and Opinion</i> , 2019 , 35, 927-935	2.5	7
107	Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019 , 94, 803-811	7.1	23
106	Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. <i>Blood</i> , 2019 , 134, 867-879	2.2	29
105	Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. <i>Blood Advances</i> , 2019 , 3, 508-518	7.8	43
104	Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. <i>Leukemia Research</i> , 2019 , 85, 106197	2.7	8
103	Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin. <i>PLoS ONE</i> , 2019 , 14, e0219547	3.7	22
102	Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study. <i>Clinical Epidemiology</i> , 2019 , 11, 769-780	5.9	1
101	1735. Epidemiology of Invasive Fungal Infections During Induction Chemotherapy in Adults With Newly Diagnosed Acute Myeloid Leukemia Without Antifungal Prophylaxis: A Retrospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S635-S636	1	78
100	2532. Identifying Educational Needs and Improving Provider Knowledge Regarding the Management of Febrile Neutropenia. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S880-S880	1	78
99	Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. <i>British Journal of Haematology</i> , 2019 , 185, 595-598	4.5	14
98	Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study. <i>British Journal of Haematology</i> , 2018 , 181, 205-214	4.5	12
97	Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). <i>Leukemia Research</i> , 2018 , 67, 17-20	2.7	16
96	Interpretation of clinical endpoints in trials of acute myeloid leukemia. <i>Leukemia Research</i> , 2018 , 68, 32-39	2.7	22
95	Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. <i>Blood Reviews</i> , 2018 , 32, 289-299	11.1	48
94	Associations between cohabitation status, treatment, and outcome in AML patients: a national population-based study. <i>Blood</i> , 2018 , 131, 2730-2733	2.2	4
93	Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 314-323	4.7	18
92	Real-World Treatment Patterns and Comparative Effectiveness Among a Population of Elderly Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018 , 132, 835-835	2.2	5
91	Increase in Chemotherapy Use and Associated Survival Benefit Among Medicare-Aged Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018 , 132, 3591-3591	2.2	2

90	Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study. <i>Blood</i> , 2018 , 132, 207-207	2.2	1
89	Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7040-7040	2.2	
88	Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. <i>Blood</i> , 2018 , 132, 1388-1388	2.2	
87	Augmentation of the Acute Myeloid Leukemia-Composite Model (AML-CM) with Performance Status and Secondary Leukemia. <i>Blood</i> , 2018 , 132, 3992-3992	2.2	1
86	The Relationship between Age and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in a Cohort of Older Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018 , 132, 3588-3588	2.2	
85	Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2018 , 103, 101-106	6.6	14
84	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2684-2692	2.2	446
83	Non-zero-sum game of transfusions: EOL in leukemia. <i>Blood</i> , 2018 , 132, 676-678	2.2	2
82	Is there a standard of care for relapsed AML?. <i>Best Practice and Research in Clinical Haematology</i> , 2018 , 31, 384-386	4.2	13
81	Functional genomic landscape of acute myeloid leukaemia. <i>Nature</i> , 2018 , 562, 526-531	50.4	391
80	A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. <i>International Journal of Hematology</i> , 2018 , 108, 267-273	2.3	1
79	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. <i>New England Journal of Medicine</i> , 2017 , 377, 454-464	59.2	1067
78	Enasidenib in mutant relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2017 , 130, 722-731	2.2	831
77	Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. <i>Cell Reports</i> , 2017 , 18, 3204-3218	10.6	104
76	Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3678-3687	2.2	24
75	Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. <i>JAMA Oncology</i> , 2017 , 3, 1675-1682	13.4	78
74	Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: A subset with possible durable remission without transplantation. <i>JAAD Case Reports</i> , 2017 , 3, 310-315	1.4	9
73	Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E7554-E7563	11.5	58

72	Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function. <i>Cancer Research</i> , 2017 , 77, 4258-4267	10.1	8
71	Novel Therapeutics in Acute Myeloid Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 495-503	7.1	11
70	Correlation between mutation clearance and clinical response in elderly patients with acute myeloid leukemia (AML) treated with azacitidine and pracinostat.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7034-7034	2.2	2
69	Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7036-7036	2.2	3
68	Quality of life of acute myeloid leukemia patients in a real-world setting.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e18525-e18525	2.2	
67	Real-world prescribing patterns in acute myeloid leukemia in the United States.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e18524-e18524	2.2	
66	Identification of Doxorubicin as an Inhibitor of the IRE1/XBP1 Axis of the Unfolded Protein Response. <i>Scientific Reports</i> , 2016 , 6, 33353	4.9	18
65	Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988-2011: a population-based study. <i>British Journal of Haematology</i> , 2016 , 173, 292-302	4.5	16
64	A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2016 , 173, 253-9	4.5	2
63	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 248-257	4.7	27
62	Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species. <i>Clinical Cancer Research</i> , 2016 , 22, 1978-88	12.9	12
61	Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2016 , 57, 609-15	1.9	19
60	A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit. <i>Blood</i> , 2016 , 128, 100-100	2.2	17
59	Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016 , 128, 1111-1111	2.2	4
58	SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016 , 128, 901-901	2.2	33
57	Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial. <i>Blood</i> , 2016 , 128, 902-902	2.2	4
56	Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial. <i>Blood</i> , 2016 , 128, 906-906	2.2	16
55	Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7000-7000	2.2	116

54	Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients. <i>Oncotarget</i> , 2016 , 7, 72044-72056	3.3	15
53	Optimizing infusion scheduling through lean methods and data science.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e18240-e18240	2.2	
52	Why do subjects on clinical trials discontinue therapy? Do we really know?. <i>Leukemia Research</i> , 2016 , 51, 19-21	2.7	
51	NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1357-1370	7.3	64
50	Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. <i>Blood</i> , 2016 , 127, 1017-23	2.2	117
49	Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. <i>Nature Medicine</i> , 2015 , 21, 178-84	50.5	341
48	Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy. <i>Cancer Discovery</i> , 2015 , 5, 988-1003	24.4	69
47	Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. <i>Bone Marrow Transplantation</i> , 2015 , 50, 1004-1006	4.4	1
46	Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis. <i>Cancer</i> , 2015 , 121, 2004-12	6.4	46
45	Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. <i>Annals of Hematology</i> , 2015 , 94, 1127-38	3	168
44	Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia. <i>Haematologica</i> , 2015 , 100, 331-5	6.6	19
43	Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3641-9	2.2	232
42	Chemotherapy options for previously untreated acute myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2149-62	4	11
41	Disparities in early death and survival in children, adolescents, and young adults with acute promyelocytic leukemia in California. <i>Cancer</i> , 2015 , 121, 3990-7	6.4	23
40	Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm. <i>Human Pathology</i> , 2015 , 46, 322-6	3.7	7
39	Predictors of Early Death and Survival Among Children, Adolescents and Young Adults with Acute Myeloid Leukemia in California, 1988-2011: A Population-Based Study. <i>Blood</i> , 2015 , 126, 1323-1323	2.2	1
38	Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. <i>Blood</i> , 2015 , 126, 323-323	2.2	55
37	Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015 , 126, 453-453	2.2	19

36	Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality. <i>Blood</i> , 2015 , 126, 532-532	2.2	4
35	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia. <i>Blood</i> , 2015 , 126, 3803-3803	2.2	93
34	A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 2553-2553	2.2	23
32	Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2014 , 164, 245-50	4.5	21
31	Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia. <i>Leukemia Research</i> , 2014 , 38, 564-8	2.7	10
30	Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. <i>Blood</i> , 2014 , 124, 385-92	2.2	159
29	Consolidation Therapy in Acute Myeloid Leukemia 2014 , 67-70		
28	Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2014 , 38, 1441-5	2.7	9
27	Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. <i>Haematologica</i> , 2013 , 98, 591-6	6.6	49
26	MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study. <i>Blood</i> , 2013 , 122, 1443-1443	2.2	4
25	BCL-2 Inhibition As a Synthetic Lethal Approach To Target Isocitrate Dehydrogenase Mutations In Acute Myeloid Leukemia Stem Cells. <i>Blood</i> , 2013 , 122, 885-885	2.2	3
24	Mcl-1 Dependence Predicts Response To Vorinostat and Gemtuzumab Ozogamicin In Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 1305-1305	2.2	
23	Mutations In UBA3 Confer Resistance To The NEDD8-Activating Enzyme Inhibitor MLN4924 In Human Leukemic Cells. <i>Blood</i> , 2013 , 122, 2527-2527	2.2	
22	Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2012 , 87, 45-50	7.1	9
21	Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. <i>Haematologica</i> , 2012 , 97, 1401-4	6.6	52
20	Unveiling the complexity of CK+ AML. <i>Blood</i> , 2012 , 119, 1958-9	2.2	
19	Impact of residual normal metaphases in core binding factor acute myeloid leukemia. <i>Cancer</i> , 2012 , 118, 2420-3	6.4	6

18	Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. <i>Blood</i> , 2012 , 120, 3594-3594	2.2	
17	Qualitative analysis of practicing oncologists' attitudes and experiences regarding HIT-facilitated collection of patient-reported outcomes.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 56-56	2.2	
16	Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype. <i>Haematologica</i> , 2011 , 96, 631-2	6.6	10
15	Cytarabine dose for acute myeloid leukemia. <i>New England Journal of Medicine</i> , 2011 , 364, 2167-8; author reply 2168-9	59.2	7
14	Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm,. <i>Blood</i> , 2011 , 118, 3617-3617	2.2	
13	Application of Mass Cytometry to Measure Proliferation During Normal and Malignant Hematopoietic Differentiation. <i>Blood</i> , 2011 , 118, 4782-4782	2.2	
12	Plasma cell leukemia: concepts and management. <i>Expert Review of Hematology</i> , 2010 , 3, 543-9	2.8	4
11	Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. <i>Blood</i> , 2010 , 116, 2224-8	2.2	157
10	Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). <i>Leukemia Research</i> , 2010 , 34, 594-7	2.7	25
9	Influence of Residual Normal Metaphases In Patients with Monosomal Karyotype.. <i>Blood</i> , 2010 , 116, 1671-1671	2.2	1
8	Update of a Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies. <i>Blood</i> , 2010 , 116, 3286-3286	2.2	1
7	The Impact of Distance to Treatment Center on the Outcome of AML. <i>Blood</i> , 2010 , 116, 4742-4742	2.2	1
6	The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study. <i>Blood</i> , 2010 , 116, 658-658	2.2	5
5	A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2010 , 116, 3288-3288	2.2	
4	Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation StatusBased Treatment Stratification. <i>Blood</i> , 2010 , 116, 3313-3313	2.2	
3	Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report. <i>Cases Journal</i> , 2009 , 2, 121		9
2	Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.. <i>Blood</i> , 2009 , 114, 1015-1015	2.2	6
1	High Risk of Early Mortality in Adult Patients with Acquired Hemophagocytic Lymphohistiocytosis.. <i>Blood</i> , 2009 , 114, 1359-1359	2.2	1

